Literature DB >> 35411078

Towards personalizing radiotherapy for brain metastasis.

.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35411078     DOI： 10.1038/s41591-022-01776-5

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

1.  Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis.

Authors:  DeeDee Smart; Alejandra Garcia-Glaessner; Diane Palmieri; Sarah J Wong-Goodrich; Tamalee Kramp; Brunilde Gril; Sudhanshu Shukla; Tiffany Lyle; Emily Hua; Heather A Cameron; Kevin Camphausen; Patricia S Steeg
Journal:  Clin Exp Metastasis       Date:  2015-08-30       Impact factor: 5.150

Review 2.  Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease.

Authors:  A H Burstein; M Sabbagh; R Andrews; C Valcarce; I Dunn; L Altstiel
Journal:  J Prev Alzheimers Dis       Date:  2018

Review 3.  Current approaches to the management of brain metastases.

Authors:  John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang
Journal:  Nat Rev Clin Oncol       Date:  2020-02-20       Impact factor: 66.675

4.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Authors:  Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley
Journal:  Lancet       Date:  2016-09-04       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.